Immunological Disorders and Immunotherapy

Immunological Disorders and Immunotherapy
Open Access

ISSN: 2593-8509

+44 7460312890

Immune responses in Covid 19

Journal of Immunological disorders and Immunotherapy

 

Journal of Immunological disorders and immunotherapy is pleased to inform about the special issue on "Immune responses in Covid 19".

 As we all know the Corona virus pandemic has engulfed every country and the entire world attention has been drawn towards one's immune system; the body’s natural defense mechanism against  microorganisms attack.

Our immune system needs to adapt to Covid 19 unaided until a vaccine is made available .A healthy lifestyle can help boost one's immune system to be in the fittest shape possible to tackle pathogens, but it’s better to stop them entering the body in the first place. Therefore, researchers must make sure that they are studying the most up-to-date version of the virus.

 

With the same purpose our Journal “Journal of Immunological disorders and Immunotherapy” is announcing Special Issue Call for paper on “Immune responses in Covid-19  ”. We welcome both solicited and unsolicited submissions that will contribute to this special issue.

 

Submission Process

 

Special issue articles can include both original unpublished research articles and review articles related to the specific theme.

Manuscripts will be accepted for publishing in the special issue only after getting approved by the peer review committee.

All the articles in special issues should strictly adhere to journal style and formatting.

Each special issue can be created with 5-7 articles.

All accepted manuscripts can be submitted online via https://www.longdom.org/submissions/immunological-disorders-immunotherapy.html or through an email id to [email protected]

Submission should be accompanied by a cover letter with reference to the concerned special issue theme.

Please visit Instruction for authors page to know more about article formatting and guidelines: https://www.longdom.org/immunological-disorders-immunotherapy/instructionsforauthors.html

Top